AI assistant
Sending…
UroGen Pharma Ltd. — Director's Dealing 2025
Dec 1, 2025
32312_dirs_2025-12-01_3a6f8e52-4e4b-409d-899d-e28b7995d72e.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: UroGen Pharma Ltd. (URGN)
CIK: 0001668243
Period of Report: 2025-11-26
Reporting Person: BUTITTA CYNTHIA M (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-11-26 | ordinary shares | M | 2000 | — | Acquired | 2000 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-11-26 | Restricted Stock Unit | $ | M | 2000 | Disposed | Ordinary Shares (2000) | Direct |
Footnotes
F1: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer
More from UroGen Pharma Ltd.
Annual Report
2026
May 27
Interim / Quarterly Report
2026
May 6
Regulatory Filings
2026
May 6
Proxy Solicitation & Information Statement
2026
Apr 30
Annual Report
2026
Mar 2
Regulatory Filings
2026
Mar 2
Regulatory Filings
2026
Mar 2
Director's Dealing
2026
Feb 27
Director's Dealing
2026
Feb 19
Director's Dealing
2026
Feb 11